Ab Index-Nr. 611-041-00-4

Index-Nr.Internationale chemische BezeichnungEG-Nr.CAS-Nr.EinstufungKennzeichnungbis 30.11.2018: Spezifische Konzentrations-
grenzen,
M-Faktoren
ab 01.12.2018: Spezifische Konzentrations-
grenzen
M-Faktoren und ATE
Anmer-
kungen
Gefahrenklasse, Gefahren-
kategorie und Gefahren-
kodierung
Kodierung der Gefahrenhin-
weise
Piktogramm, Kodierung der SignalworteKodierung der Gefahrenhin-
weise
Kodierung der ergänzenden Gefahren-
merkmale
611-041-00-42-[[4[[4,6-bis[[3-(diethylami-
no)propyl]amino]-1,3,5-triazi-
ne-2-yl]amino]phenyl]azo]-N-
(2,3-dihydro-2-oxo-1H-benzi-
midazol-5-yl)-3-oxobutanamide
407-680-198809-11-1Eye Dam. 1
Skin Sens. 1
Aquatic Chronic 2
H318
H317
H411
GHS05
GHS07
GHS09
Dgr
H318
H317
H411
   
611-042-00-Xtrisodium
5-amino-3-[5-(2-bromoacryloy-
lamino)-2-sulfonatophenylazo]-
4-hydroxy-6-(4-vinylsulfonyl-
phenylazo)naphthalene-2,7-
disulfonate
411-770-6136213-71-3Aquatic Chronic 3H412H412   
611-043-00-5reaction mass of: trisodium
N(1')-N(2):N(1''')-N(2'')-η-6-
[2-amino-4-(or 6)-hydroxy-(or 4-amino-2-hydroxy)phenylazo]-
6''-(1-carbaniloyl-2-hydroxy-
prop-1-enylazo)-5',5'''-disulfa-
moyl-3,3''-disulfonatobis(naph-
thalene-2,1'-azobenzene-1,2'-
diolato-O(1),O(2'))-chromate;
trisodium N(1')-N(2):N(1''')-
N(2'')-η-6,6''-bis(1-carba-
niloyl-2-hydroxyprop-1-
enylazo)-5',5'''-disulfamoyl-
3,3''-disulfonatobis(naph-
thalene-2,1'azobenzene-1,2'-
diolato-O(1),O(2'))-chromate;
trisodium N(1')-N(2):N(1''')-
N(2'')-η-6,6''-bis
[2-amino-4-(or 6)-hydroxy-
(or 4-amino-2-hydroxy)phenyl-
azo]5',5'''-disulfamoyl-3,3''-
disulfonatobis(naphthalene-
2,1'azobenzene-1,2'-diolato-
O(1),O(2'))-chromate (2:1:1)
402-850-1Eye Dam. 1
Aquatic Chronic 3
H318
H412
GHS05
Dgr
H318
H412
   
611-044-00-0reaction mass of:
tert-alkyl(C12-C14)ammo-
nium bis[1-[(2-hydroxy-5-
nitrophenyl)azo]-
2-naphthalenolato(2-)]-
chromate(1-);
tert-alkyl(C12-C14)ammonium bis[1-[(2-hydroxy-4-nitro-
phenyl)azo]-2-naphthalenolato
(2-)]-chromate(1-);
tert-alkyl(C12-C14)ammonium bis[1-[[5-(1,1-dimethylpropyl)-
2-hydroxy-3-nitrophenyl]
azo]-2-naphthalenolato(2-)]-
chromate(1-);
tert-alkyl(C12-C14)ammonium [[1-[(2-hydroxy-5-nitrophe-
nyl)azo]-2-naphthalenolato
(2-)]-[1-[(2-hydroxy-5-nitrophe-
nyl)azo]-2-naphthalenola-
to(2-)]]-chromate(1-);
tert-alkyl(C12-C14)ammonium [[1-[[5-(1,1-dimethylpropyl)-
2-hydroxy-3-nitrophenyl]
azo]-2-naphthalenolato(2-)]-[1-
[(2-hydroxy-5-nitrophenyl)azo]-
2-naphthalenolato(2-)]]-
chromate(1-);
tert-alkyl(C12-C14)ammonium ((1-(4(or 5)-nitro-2-oxidophe-
nylazo)-2-naphtholato)(1-
(3-nitro-2-oxido-5-pentyl-
phenylazo)-2-naphthola-
to))chromate(1-)
403-720-7117527-94-3Aquatic Chronic 2H411GHS09H411   
611-045-00-62-[4-[N-(4-acetoxybutyl)-N-
ethyl]amino-2-methylphenyl-
azo]-3-acetyl-5-nitrothio-
phene
404-830-8Aquatic Chronic 4H413H413   
611-046-00-14,4'-diamino-2-methylazo-
benzene
407-590-243151-99-1Acute Tox. 3 (*)
STOT RE 2 (*)
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
H301
H373 (*)(*)
H317
H400
H410
GHS06
GHS08
GHS09
Dgr
H301
H373 (*)(*)
H317
H410
   
611-047-00-7reaction mass of:
2-[[4-[N-ethyl-N-(2-aceto-
xyethyl)amino]phenyl]azo]-
5,6-dichlorobenzothiazole;
2-[[4-[N-ethyl-N-(2-acetoxy-
ethyl)amino]phenyl]azo]-6,7-
dichlorobenzothiazole (1:1)
407-890-3111381-11-4Aquatic Chronic 4H413H413   
611-048-00-2reaction mass of:
2-[[4-[bis(2-acetoxyethyl)
amino]phenyl]azo]-5,6-di-
chlorobenzothiazole;
2-[[4-[bis(2-acetoxyethyl)ami-
no]phenyl]azo]-6,7-dichloro-
benzothiazole (1:1)
407-900-6111381-12-5Aquatic Chronic 4H413H413   
611-049-00-8reaction mass of
7-[4-(3-diethylaminopro-
pylamino)-6-(3-diethylam-
moniopropylamino)-1,3,5-
triazin-2-ylamino]-4-hydroxy-
3-(4-phenylazophenylazo)-
naphthalene-2-sulfonate, acetic acid, lactic acid (2:1:1)
408-000-6118658-98-3STOT RE 2 (*)
Skin Sens. 1
Aquatic Chronic 3
H373 (*)(*)
H317
H412
GHS08
Wng
H373 (*)(*)
H317
H412
   
611-050-00-3reaction mass of: pentasodium
7-amino-3-[[4-[[4-[[4-[[4-[(6-
amino-1-hydroxy-3-sulfonato-2-
naphthyl)azo]-7-sulfonato-1-
naphthyl]azo]phenyl]amino]-3-
sulfonatophenyl]azo]-6-
sulfonato-1-naphthyl]azo]-4-
hydroxynaphthalen-
2-sulfonate;
pentasodium 7-amino-8-[4-[4-
[4-[4-(2-amino-5-hydroxy-7-
sulfonatonaphthalen-1-ylazo)-
7-sulfonatonaphthalen-1-ylazo]-
phenylamino]-3-sulfonato-
phenylazo]-6-sulfonato-
naphthalen-1-ylazo]-4-hydroxy-
naphthalene-2-sulfonate;
pentasodium 7-amino-8-[4-[4-
[4-[4-(6-amino-1-hydroxy-3-
sulfonato-naphthalen-1-ylazo)-
7-sulfonatonaphthalen-1-
ylazo]-phenylamino]-3-
sulfonato-phenylazo]-6-
sulfonato-naphthalen-1-ylazo]-
4-hydroxy-naphthalene-2-
sulfonate;
tetrasodium 7-amino-4-hydroxy-3-
[4-[4-[4-(4-hydroxy-7-sulfonato-
naphthalen-1-ylazo)-2-sulfonato-
phenylamino]phenylazo]-6-
sulfonato-naphthalen-1-
ylazo]naphthalene-2-sulfonate;
tetrasodium 7-amino-4-hydroxy-3-
[4-[4-[4-(4-amino-7-sulfonato-
naphthalen-1-ylazo)-2-sulfonato-
phenylamino]phenylazo]-6-
sulfonato-naphthalen-1-
ylazo]naphthalene-2-sulfonate
415-350-3Eye Dam. 1
Aquatic Chronic 3
H318
H412
GHS05
Dgr
H318
H412
   
611-051-00-92-(4-(N-ethyl-N-(2-
hydroxy)ethyl)amino-2-
methylphenyl)azo-6-methoxy-
3-methylbenzothiazolium chloride
411-110-7136213-74-6Aquatic Acute 1
Aquatic Chronic 1
H400
H410
GHS09
Wng
H410   
611-052-00-4monosodium aqua-[5-[[2,4-dihydroxy-5-
[(2-hydroxy-3,5-dinitrophenyl)azo]phenyl]
azo]-2-naphthalensulfonate], iron complex
400-720-9Aquatic Chronic 3H412H412   
611-053-00-X2,2'-azobis[2-methylpropio-
namidine] dihydrochloride
221-070-02997-92-4Acute Tox. 4 (*)
Skin Sens. 1
H302
H317
GHS07
Wng
H302
H317
   
611-055-00-0C.I. Disperse Yellow 3;
N-[4-[(2-hydroxy-5-methyl-
phenyl)azo]phe-
nyl]acetamide
220-600-82832-40-8Carc. 2
Skin Sens. 1
H351
H317
GHS08
GHS07
Wng
H351
H317
   
611-056-00-6C.I. Solvent Yellow 14;
1-phenylazo-2-naphthol
212-668-2842-07-9Carc. 2
Muta. 2
Skin Sens. 1
Aquatic Chronic 4
H351
H341
H317
H413
GHS08
GHS07
Wng
H351
H341
H317
H413
   
611-057-00-16-hydroxy-1-(3-isopropoxy-
propyl)-4-methyl-2-oxo-5-[4-
(phenylazo)phenylazo]-1,2-
dihydro-3-pyridinecarbonitrile
400-340-385136-74-9Carc. 1B
Aquatic Chronic 4
H350
H413
GHS08
Wng
H350
H413
   
611-058-00-7(6-(4-hydroxy-3-(2-methoxy-
phenylazo)-2-sulfonato-7-
naphthylamino)-1,3,5-triazin-
2,4-diyl)bis[(amino-1-methyl-
ethyl)ammonium] formate
402-060-7108225-03-2Carc. 1B
Eye Dam. 1
Aquatic Chronic 2
H350
H318
H411
GHS08
GHS05
GHS09
Dgr
H350
H318
H411
   
611-059-00-2octasodium 2-(6-(4-chloro-6-
(3-(N-methyl-N-(4-chloro-6-
(3,5-disulfonato-2-naphthy-
lazo)-1-hydroxy-6-naphthyl-
amino)-1,3,5-triazin-2-yl)amino-
methyl)phenylamino)-
1,3,5-triazin-2-ylamino)-3,5-
disulfonato-1-hydroxy-2-
naphthylazo)naphthalene-
1,5-disulfonate
412-960-1148878-21-1Eye Dam. 1
Skin Sens. 1
Aquatic Chronic 3
H318
H317
H412
GHS05
GHS07
Dgr
H318
H317
H412
   
611-060-00-8reaction mass of: sodium 5-[8-[4-[4-[4-[7-(3,5-di-
carboxylatophenylazo)-8-
hydroxy-3,6-disulfonato-
naphthalen-1-ylamino]-6-
hydroxy-1,3,5-triazin-2-yl]-2,5-
dimethylpiperazin-1-yl]-6-
hydroxy-1,3,5-triazin-2-yla-
mino]-1-hydroxy-3,6-disulfona-
tonaphthalen-2-ylazo]-iso-
phthalate;
ammonium 5-[8-[4-[4-[4-
[7-(3,5-dicarboxylatophenyla-
zo)-8-hydroxy-3,6-disulfona-
tonaphthalen-1-ylamino]-6-
hydroxy-1,3,5-triazin-2-yl]-2,5-
dimethylpiperazin-1-yl]-6-
hydroxy-1,3,5-triazin-2-ylami-
no]-1-hydroxy-3,6-disulfonato-
naphthalen-2-ylazo]-iso-
phthalate;
5-[8-[4-[4-[4-[7-(3,5-dicarboxy-
latophenylazo)-8-hydroxy-3,6-
disulfonatonaphthalen-
1-ylamino]-6-hydroxy-1,3,5-
triazin-2-yl]-2,5-dimethyl-
piperazin-1-yl]-6-hydroxy-
1,3,5-triazin-2-ylamino]-1-
hydroxy-3,6-disulfonaph-
thalen-2-ylazo]-isophthalic acid
413-180-4187285-15-0Eye Dam. 1H318GHS05
Dgr
H318   
611-061-00-3disodium 5-[5-[4-(5-chloro-
2,6-difluoropyrimidin-4-ylami-
no)benzamido]-2-sulfonato-
phenylazo]-1-ethyl-6-hydroxy-
4-methyl-2-oxo-3-pyridyl-
methylsulfonate
412-530-3Eye Dam. 1
Skin Sens. 1
H318
H317
GHS05
GHS07
Dgr
H318
H317
   
611-062-00-9octasodium 2-(8-(4-chloro-
6-(3-((4-chloro-6-(3,6-
disulfonato-2-(1,5-disulfona-
tonaphthalen-2-ylazo)-1-
hydroxynaphthalen-8-ylamino)-
1,3,5-triazin-2-yl)amino-
methyl)phenylamino)-1,3,5-
triazin-2-ylamino)-3,6-
disulfonato-1-hydroxy-
naphthalen-2-ylazo)
naphthalene-1,5-disulfonate
413-550-5Skin Irrit. 2
Eye Dam. 1
H315
H318
GHS05
Dgr
H315
H318
   
611-063-00-4trisodium [4'-(8-acetylamino-
3,6-disulfonato-2-naphthylazo)-
4''-(6-benzoylamino-3-
sulfonato-2-naphthylazo)-
biphenyl-1,3',3'',1'''-tetraolato-
O,O',O'',O''']copper(II)
413-590-3164058-22-4Carc. 1BH350GHS08
Dgr
H350   
611-064-00-X4-(3,4-dichlorophenylazo)-2,6-
di-sec-butylphenol
410-600-8124719-26-2STOT RE 2 (*)
Skin Irrit. 2
Aquatic Acute 1
Aquatic Chronic 1
H373 (*)(*)
H315
H400
H410
GHS08
GHS07
GHS09
Wng
H373 (*)(*)
H315
H410
   
611-065-00-54-(4-nitrophenylazo)-2,6-di-
sec-butyl-phenol
410-610-2111850-24-9STOT RE 2 (*)
Eye Irrit. 2
Skin Irrit. 2
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
H373 (*)(*)
H319
H315
H317
H400
H410
GHS08
GHS07
GHS09
Wng
H373 (*)(*)
H319
H315
H317
H410
   
611-066-00-0tetrasodium
5-[4-chloro-6-(N-ethyl-anilino)-
1,3,5-triazin-2-ylamino]-4-
hydroxy-3-(1,5-disulfonato-
naphthalen-2-ylazo)-
naphthalene-2,7-disulfonate
411-540-5130201-57-9Eye Dam. 1
Skin Sens. 1
Aquatic Chronic 2
H318
H317
H411
GHS05
GHS07
GHS09
Dgr
H318
H317
H411
   
611-067-00-6reaction mass of:
bis(tris(2-(2-hydroxy
(1-methyl)ethoxy)ethyl)am-
monium)7-anilino-4-hydroxy-
3-(2-methoxy-5-methyl-
4-(4-sulfonatophenylazo)phe-
nylazo)naphthalene-2-sulfonate;
bis(tris(2-(2-hydroxy(2-
methyl)ethoxy)ethyl)am-
monium) 7-anilino-4-hydroxy-
3-(2-methoxy-5-methyl-4-
(4-sulfonatophenylazo)phe-
nylazo)naphthalene-2-sulfonate
406-910-8Acute Tox. 4 *
Aquatic Chronic 3
H302
H412
GHS07
Wng
H302
H412
   
611-068-00-1tetrasodium 4-amino-3,6-
bis(5-[4-chloro-6-
(2-hydroxyethylamino)-1,3,5-
triazin-2-ylamino]-2-sulfona-
tophenylazo)-5-hydroxy-
naphthalene-2,7-disulfonate
400-690-785665-98-1Aquatic Chronic 2H411GHS09H411   
611-069-00-7N,N-di-[poly(oxyethylene)-co-
poly(oxypropylene)]-4-[(3,5-
dicyano-4-methyl-2-thienyl)
azo)]-3-methylaniline
413-380-1Aquatic Chronic 2H411GHS09H411   
611-070-00-2reaction mass of: disodium (6-(4-anisidino)-3-sulfonato-2-
(3,5-dinitro-2-oxidopheny-
lazo)-1-naphtholato)(1-(5-
chloro-2-oxidophenylazo)-2-
naphtholato)chromate(1-);
trisodium bis(5-(4-anisidino)-
3-sulfonato-2-(3,5-dinitro-2-
oxidophenylazo)-1-naphtho-
lato)chromate(1-)
405-665-4Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
H317
H400
H410
GHS07
GHS09
Wng
H317
H410
   
611-071-00-8tris(tetramethylammonium) 5-hydroxy-1-(4-sulphonato-
phenyl)-4-(4-sulphonatopheny-
lazo)pyrazole-3-carboxylate
406-073-9131013-81-5Acute Tox. 3 (*)
Aquatic Chronic 3
H301
H412
GHS06
Dgr
H301
H412
   
611-072-00-32,4-bis[2,2'-[2-(N,N-dimethyl-
amino)ethyloxycarbonyl]phe-
nylazo]-1,3-dihydroxyben-
zene, dihydrochloride
407-010-8118208-02-9Acute Tox. 4 (*)
Eye Dam. 1
Aquatic Chronic 2
H302
H318
H411
GHS05
GHS07
GHS09
Dgr
H302
H318
H411
   
611-073-00-9dimethyl 3,3'-(N-(4-(4-bromo-
2,6-dicyanophenylazo)-3-
hydroxyphenyl)imino)dipro-
pionate
407-310-9122630-55-1Aquatic Chronic 4H413H413   
611-074-00-4reaction mass of: sodium/potassium (3-(4-(5-
(5-chloro-2,6-difluoropyri-
midin-4-ylamino)-2-methoxy-
3-sulfonatophenylazo)-2-
oxidophenylazo)-2,5,7-trisul-
fonato-4-naphtholato)copper(II);
sodium/potassium (3-(4-(5-
(5-chloro-4,6-difluoropyrimidin-
2-ylamino)-2-methoxy-3-
sulfonatophenylazo)-2-oxido-
phenylazo)-2,5,7-trisulfonato-
4-naphtholato)copper(II)
407-100-7Skin Sens. 1H317GHS07
Wng
H317   
611-075-00-Xreaction mass of: tris(3,5,5-
trimethylhexylammonium)
4-amino-3-(4-(4-(2-amino-4-
hydroxyphenylazo)anilino)-3-
sulfonatophenylazo)-5,6-
dihydro-5-oxo-6-phenylhydra-
zononaphthalene-2,7-
disulfonate;
tris(3,5,5-trimethylhexylam-
monium) 4-amino-3-(4-(4-
(4-amino-2-hydroxypheny-
lazo)anilino)-3-sulfonatophe-
nylazo)-5,6-dihydro-5-oxo-
6-phenylhydrazononaphtha-
lene-2,7-disulfonate (2:1)
406-000-0Eye Dam. 1
Aquatic Chronic 2
H318
H411
GHS05
GHS09
Dgr
H318
H411
   
611-076-00-53-(2,6-dichloro-4-nitro-
phenylazo)-1-methyl-2-
phenylindole
406-280-4117584-16-4Aquatic Acute 1
Aquatic Chronic 1
H400
H410
GHS09
Wng
H410   
611-077-00-0dilithium disodium (5,5'-diamino-
(μ-4,4'-dihydroxy-1:2-
κ-2,O4,O4',-3,3'-[3,3'-
dihydroxy-1:2-κ-2-
O3,O3'-biphenyl-4,4'-ylenebi-
sazo-1:2-(N3,N4-η:N3',N4'-
η)]-dinaphthalene-2,7-
disulfonato(8)))dicuprate(2-)
407-230-4126637-70-5Acute Tox. 4 (*)
Skin Sens. 1
H302
H317
GHS07
Wng
H302
H317
   
611-078-00-6(2,2'-(3,3'-dioxidobiphenyl-4,4'-
diyldiazo)bis(6-(4-(3-(diethyl-
amino)propylamino)-6-(3-
(diethylammonio)propylamino)-
1,3,5-triazin-2-ylamino)-3-
sulfonato-1-naphtholato))
dicopper(II) acetate lactate
407-240-9159604-94-1Skin Sens. 1
Aquatic Chronic 2
H317
H411
GHS07
GHS09
Wng
H317
H411
   
611-079-00-1disodium 7-[4-chloro-6-(N-ethyl-o-tolui-
dino)-1,3,5-triazin-2-ylamino]-
4-hydroxy-3-(4-methoxy-2-
sulfonatophenylazo)-2-naph-
thalenesulfonate
410-390-8147703-64-8Eye Dam. 1H318GHS05
Dgr
H318   
611-080-00-7sodium 3-(2-acetamido-
4-(4-(2-hydroxybu-
toxy)phenylazo)phenyl-
azo)benzenesulfonate
410-150-2147703-65-9Skin Sens. 1H317GHS07
Wng
H317   
611-081-00-2tetrasodium [7-(2,5-dihydroxy-
KO2-7-sulfonato-6-[4-(2,5,6-
trichloro-pyrimidin-4-yla-
mino)phenylazo]-(N1,N7-N)-1-
naphthy-lazo)-8-hydroxy-
KO8-naphthalene-1,3,5-tri-
sulfonato(6-)]cuprate(II)
411-470-5141048-13-7Skin Sens. 1
Aquatic Chronic 3
H317
H412
GHS07
Wng
H317
H412
   
611-082-00-8reaction mass of: pentasodium bis(1-(3(or 5)-(4-anilino-3-
sulfonatophenylazo)-4-hyd-
roxy-2-oxidophenylazo)-6-nitro-
4-sulfonato-2-naphtholato)fer-
rate(1-);
pentasodium [(1-(3-(4-anilino-
3-sulfonatophenylazo)-4-
hydroxy-2-oxidophenylazo)-
6-nitro-4-sulfonato-2-naphtho-
lato)-(5-(4-anilino-3-sulfona-
tophenylazo)-4-hydroxy-2-
oxidophenylazo)-6-nitro-4-
sulfonato-2-
naphtholato]ferrate(1-)
407-570-3Aquatic Chronic 2H411GHS09H411   
611-083-00-3reaction mass of: 2-[N-ethyl-4-[(5,6-dichlo-
robenzothiazol-2-yl)azo]-m-
toludino]ethylacetate;
2-[N-ethyl-4-[(6,7-dichloroben-
zothiazol-2-yl)azo]-m-
toludino]ethyl acetate (1:1)
411-560-4STOT RE 1
Skin Sens. 1
Aquatic Chronic 2
H372 (*)(*)
H317
H411
GHS08
GHS07
GHS09
Dgr
H372 (*)(*)
H317
H411
   
611-085-00-4reaction mass of:
3-cyano-5-(2-cyano-4-
nitro-phenylazo)-2-(2-hydroxy-
ethylamino)-4-methyl-6-[3-(2-
phenoxyethoxy)propyla-
mino]pyridine;
3-cyano-5-(2-cyano-4-nitro-
phenylazo)-6-(2-hydroxy-
ethylamino)-4-methyl-2-[3-(2-
phenoxyethoxy)propylami-
no]pyridine;
3-cyano-5-(2-cyano-4-nitro-
phenylazo)-2-amino-4-methyl-
6-[3-(3-hydroxypropoxy)
propylamino]pyridine;
3-cyano-5-(2-cyano-4-nitro-
phenylazo)-6-amino-4-methyl-
2-[3-(3-methoxypropoxy)
propylamino]pyridine
411-880-4Skin Sens. 1
Aquatic Chronic 2
H317
H411
GHS07
GHS09
Wng
H317
H411
   
611-086-00-Xmonolithium 5-[[2,4-dihydroxy-
5-[(2-hydroxy-3,5-dinitrophenyl)azo]phenyl]azo]-2-
naphthalenesulfonate], iron complex, monohydrate
411-360-7Aquatic Chronic 3H412H412   
611-087-00-5reaction mass of:
3-((5-cyano-1,6-dihydro-
1,4-dimethyl-2-hydroxyl-6-
oxo-3-pyridinyl)
azo)-benzoyloxy-2-
phenoxyethane;
3-((5-cyano-1,6-dihydro-1,4-
dimethyl-2-hydroxy-6-oxo-3-
pyridinyl)azo)-benzoyloxy-
2-ethyloxy-2-(ethylphenol)
411-710-9Aquatic Chronic 4H413H413   
611-088-00-0reaction mass of: trilithium 4-amino-3-((4-((4-((2-amino-
4-hydroxyphenyl)azo)phenyl)
amino)-3-sulfophenyl)azo)-5-
hydroxy-6-(phenylazo)naph-
thalene-2,7-disulfonate;
trilithium 4-amino-3-((4-
((4-((4-amino-2-hydroxy-
phenyl)azo)phenyl)amino)-3-
sulfophenyl)azo)-5-hydroxy-6-
(phenylazo)naph-
thalene-2,7-disulfonate
411-890-9Acute Tox. 4 (*)
Eye Dam. 1
Aquatic Chronic 3
H302
H318
H412
GHS05
GHS07
Dgr
H302
H318
H412
   
611-089-00-62-((4-(ethyl-(2-hydroxyethyl)a-
mino)-2-methylphenyl)azo)-6-
methoxy-3-methyl-
benzothiazolium methylsulfate
411-100-2136213-73-5STOT RE 2 (*)
Skin Sens. 1
Aquatic Acute 1
Aquatic Chronic 1
H373 (*)(*)
H317
H400
H410
GHS08
GHS07
GHS09
Wng
H373 (*)(*)
H317
H410
   
611-090-00-12,5-dibutoxy-4-(morpholin-4-
yl)benzenediazonium 4-methylbenzenesulfonate
413-290-293672-52-7Self-react. C
Acute Tox. 4 (*)
Eye Dam. 1
Skin Sens. 1
Aquatic Chronic 3
H242
H302
H318
H317
H412
GHS02
GHS05
GHS07
Dgr
H242
H302
H318
H317
H412
  T
611-091-00-7sodium (1,0-1,95)/lithium (0,05-1) 5-((5-((5-chloro-6-
fluoro-pyrimidin-4-yl)amino)-
2-sulfonatophenyl)azo)-1,2-
dihydro-6-hydroxy-1,4-di-
methyl-2-oxo-3-pyridinemethyl-
sulfonate
413-470-0134595-59-8Skin Sens. 1H317GHS07
Wng
H317   
611-092-00-2tert-(dodecyl/tetradecyl)-am-
monium bis(3-(4-((5-(1,1-
dimethyl-propyl)-2-hydroxy-3-
nitrophenyl)azo)-3-methyl-5-
hydroxy-(1H)pyrazol-1-yl)ben-
zenesulfonamidato)chromate
413-210-6Aquatic Chronic 2H411GHS09H411   
611-093-00-8sodium 2-(4-(4-fluoro-6-(2-
sulfo-ethylamino)-[1,3,5]triazin-
2-ylamino)-2-ureido-
phenylazo)-5-(4-sulfophenyl-
azo)benzene-1-sulfonate
410-770-3146177-84-6Skin Sens. 1H317GHS07
Wng
H317   
611-094-00-3reaction mass of: 2-[2-acetylamino-4-[N,N-bis[2-
ethoxycarbonyloxy)ethyl]ami-
no]phenylazo]-5,6-dichloro-
1,3-benzothiazole;
2-[2-acetylamino-4-[N,N-bis[2-
ethoxy-carbonyloxy)ethyl]ami-
no]phenylazo]-6,7-dich-
loro-1,3-benzotriazole (1:1)
411-600-0143145-93-1Aquatic Chronic 4H413H413   
611-095-00-9hexasodium 1,1'-[(1-amino-8-hydroxy-3,6-
disulfonate-2,7-naphthalene-
diyl)bis(azo(4-sulfonate-1,3-
phenyl)imino[6-[(4-chloro-3-
sulfonatophenyl)amino]-1,3,5-
triazin-2,4-diyl]]]bis[3-carboxy-
pyridinium] dihydroxide
412-240-789797-03-5Aquatic Chronic 2H411GHS09H411   
611-096-00-4methyl N-[3-acetylamino)-4-(2-
cyano-4-nitrophenylazo)phe-
nyl]-N-[(1-methoxy)acetyl]
glycinate
413-040-2149850-30-6Skin Sens. 1H317GHS07
Wng
H317   
611-097-00-Xreaction mass of iron complexes of:
1,3-dihydroxy-4-[(5-phenyl-
aminosulfonyl)-2-hydroxy-
phenylazo]-n-(5-amino-
sulfonyl-2-hydroxyphenyl-
azo)benzene and: 1,3-dihyd-
roxy-4-[(5-phenylaminosulfo-
nyl)-2-hydroxyphenylazo]-n-
[4-(4-nitro-2-sulfophenyla-
mino)phenylazo]benzene (n=2,5,6)
414-150-3Skin Sens. 1
Aquatic Chronic 2
H317
H411
GHS07
GHS09
Wng
H317
H411
   
611-098-00-5tetrakis(tetramethylam-
monium)3,3'-(6-(2-
hydroxyethylamino)1,3,5-
triazine-2,4-diylbisimino(2-
methyl-4,1-phenyleneazo))bis-
naphthalene-1,5-disulfonate
405-950-3131013-83-7Acute Tox. 3 (*)
Aquatic Chronic 3
H301
H412
GHS06
Dgr
H301
H412
   
611-099-00-0(methylenebis(4,1-phenylen-
azo(1-(3-(dimethylamino)pro-
pyl)-1,2-dihydro-6-hydroxy-
4-methyl-2-oxopyridine-5,3-
diyl)))-1,1'-dipyridinium dichloride dihydrochloride
401-500-5118658-99-4Carc. 1B
Aquatic Chronic 2
H350
H411
GHS08
GHS09
Dgr
H350
H411
   
611-100-00-4potassium sodium 3,3'-(3(or4)-methyl-1,2-
phenylenebis(imino(6-chloro)-
1,3,5-triazine-4,2-diylimino(2-
acetamido-5-methoxy)-4,1-
phenylenazo)dinaphthalene-
1,5-disulfonate
403-810-6140876-13-7Eye Dam. 1H318GHS05
Dgr
H318   
611-101-00-X2'-(4-chloro-3-cyano-5-formyl-2-
thienyl)azo-5'-diethylamino-
acetanilide
405-200-5104366-25-8Skin Sens. 1H317GHS07
Wng
H317   
611-102-00-5reaction product of: C.I. Leuco Sulfur
Black 1 and reaction mass of:
disodium-4-{4-[8-amino-1-
hydroxy-7-(4-sulfamoyl-
phenylazo)-3,6-disulfonato-2-
naphthylazo]phenylsulfonyl-
amino}
benzendiazoniumchlorid;
disodium-4-{4-[2,6-dihydroxy-
3-(8-hydroxy-3,6-disulfonato-1-
naphthylazo)phenylazo]
phenylsulfonylamino}benzen-
diazoniumchlorid
424-500-7Aquatic Chronic 3H412H412   
611-103-00-0trisodium
(1-(3-carboxylato-2-oxido-5-sul-
fonatophenylazo)-5-hydroxy-
7-sulfonatonaphthalen-2-
amido)nickel(II)
407-110-1Eye Dam. 1
Skin Sens. 1
Aquatic Chronic 2
H318
H317
H411
GHS05
GHS07
GHS09
Dgr
H318
H317
H411
   
611-104-00-6reaction mass of: trisodium
(2,4(or 2,6 or
4,6)-bis(3,5-dinitro-2-oxido-
phenylazo)-5-hydroxyphenolato)
(2(or 4or 6)-(3,5-dinitro-
2-oxidophenylazo)-5-hydroxy-
4(or 2or 6)-(4-(4-nitro-2-
sulfonatoanilino)phenylazo)
phenolato)ferrate(1-);
trisodium bis(2,4(or 2,6 or 4,6)-bis(3,5-dinitro-2-
oxidophenylazo)-5-hydroxy-
phenolato)ferrate(1-);
trisodium (2,4(or 2,6 or 4,6)-bis(3,5-dinitro-
2-oxidophenylazo)-5-hydroxy-
phenolato)(2(or 4 or 6)-(3,5-dinitro-2-
oxidophenylazo)-
5-hydroxy-4(or 2 or 6)-(4-nitro-2-sulfona-
tophenylazo)phenolato)fer-
rate(1-);
trisodium (2,4(or 2,6 or 4,6)-bis(3,5-dinitro-
2-oxidophenylazo)-5-
hydroxyphenolato)(2
(or 4 or 6)-(3,5-dinitro-2-
oxidophenylazo)-
5-hydroxy-4(or 2 or 6)-(3-sulfonatopheny-
lazo)phenolato)ferrate(1-);
disodium 3,3'-(2,4-dihydroxy-1,3(or 1,5 or
3,5)-phenylenediazo)diben-
zenesulfonate
406-870-1Skin Sens. 1
Aquatic Chronic 2
H317
H411
GHS07
GHS09
Wng
H317
H411
   
611-105-00-1sodium
4-(4-chloro-6-(N-ethylanilino)-
1,3,5-triazin-2-ylamino)-2-(1-
(2-chlorophe-
nyl)-5-hydroxy-3-methyl-1H-
pyrazol-4-
ylazo)benzenesulfonate
407-800-2136213-75-7Skin Sens. 1
Aquatic Chronic 2
H317
H411
GHS07
GHS09
Wng
H317
H411
   
611-106-00-7hexasodium
4,4'-dihydroxy-3,3'-bis[2-sulfo-
nato-4-(4-sulfonatophenyl-
azo)phenylazo]-
7,7'[p-phenylenebis[imino(6-
chloro-1,3,5-triazine-4,2-
diyl)imino]]dinaphthalene-2-
sulfonate
410-180-6157627-99-1Eye Dam. 1H318GHS05
Dgr
H318   
611-107-00-2potassium sodium
4-(4-chloro-6-(3,6-disul-
fonato-7-(5,8-disulfonato-
naphthalen-2-
ylazo)-8-hydroxy-naphthalen-
1-ylamino)-1,3,5-triazin-2-
ylamino)-5-hydroxy-6-(4-(2-
sulfatoethanesulfonyl)-
phenylazo)-naphtha-
lene-1,7-disulfonate
412-490-7Skin Sens. 1H317GHS07
Wng
H317   
611-108-00-8disodium
5-((4-((4-chloro-3-sulfonatophe-
nyl)azo)-1-naphthyl)azo)-8-
(phenylamino)-
1-naphthalenesulfonate
413-600-66527-62-4Aquatic Chronic 3H412H412   
611-109-00-3reaction products of: copper(II) sulfate and
tetrasodium 2,4-bis[6-(2-
methoxy-5-sulfo-
natophenylazo)-5-hydroxy-7-
sulfonato-2-
naphthylamino]-6-(2-
hydroxyethylamino)-
1,3,5-triazine (2:1)
407-710-3Aquatic Chronic 2H411GHS09H411   
611-110-00-9tetra-sodium/lithium
4,4'-bis-(8-amino-3,6-
disulfonato-1-naphthol-2-
ylazo)-3-methyla-
zobenzene
408-210-8124605-82-9Skin Sens. 1
Aquatic Chronic 2
H317
H411
GHS07
GHS09
Wng
H317
H411
   
611-111-00-4disodium 2-[[4-(2-
chloroethylsulfonyl)phe-
nyl]-[(2-hydroxy-5-sulfo-3-
[3-[2-(2-(sul-
fooxy)ethylsulfonyl)ethylazo]-
4-sulfoben-
zoato(3-)cuprate(1-)
414-230-8Skin Sens. 1H317GHS07
Wng
H317   
611-112-00-Xtetrasodium
4-hydroxy-5-[4-[3-(2-sulfatoe-
thanesulfonyl)phenylamino]-
6-morpholin-4-yl-1,3,5-triazin-
2-ylamino]-3-(1-sulfona-
tonaphthalen-2-
ylazo)naphthalene-2,7-
disulfonate
413-070-6Skin Sens. 1H317GHS07
Wng
H317   
611-113-00-5lithium sodium
(2-(((5-((2,5-dichlorophenyl)
azo)-2-hydroxyphenyl)methy-
lene)amino)
benzoato(2-))(2-((4,5-dihydro-
3-methyl-5-oxo-1-phenyl-1H-
pyrazol-4-yl)azo)-5-sulfo-
benzoato(3-)) chromate(2-)
414-280-0149626-00-6Aquatic Chronic 2H411GHS09H411   
611-114-00-0lithium sodium
(4-((5-chloro-2-hydroxy-
phenyl)azo)-2,4-dihydro-5-
methyl-3H-pyra-
zol-3-onato(2-))(3-((4,5-
dihydro-3-methyl-
1-(4-methylphenyl)-5-oxo-
1H-pyrazol-4-yl)
azo)-4-hydroxy-5-
nitrobenzenesulfonato(3-)) chromate(2-)
414-250-7149564-66-9Acute Tox. 4 (*)
Eye Dam. 1
Aquatic Chronic 3
H302
H318
H412
GHS05
GHS07
Dgr
H302
H318
H412
   
611-115-00-6trilithium
bis(4-((4-(diethylamino)-2-
hydro-xyphenyl)azo)-3-
hydroxy-1-naphthalenesul-
fonato(3-))chromate(3-)
414-290-5149564-65-8Acute Tox. 4 (*)
Aquatic Chronic 3
H302
H412
GHS07
Wng
H302
H412
   
611-116-00-1reaction mass of: trisodium 5-{4-chloro-6-[2-(2,6-dichloro-
5-cyanopyrimidin-4-yla-
mino)-propylamino]-1,3,5-
triazin-2-yla-
mino}-4-hydroxy-3-(1-
sulfonatonaphtha-
lene-2-ylazo)-naphthalene-
2,7-disulfonate;
 
trisodium 5-{4-chloro-6-
[2-(2,6-dichloro-5-
cyanopyrimidin-4-ylamino)-
1-methyl-ethy-
lamino]-1,3,5-triazin-2-
ylamino}-4-hydroxy-3-(1-
sulfonatonaphthalene-2-ylazo)-
naphthalene-2,7-disulfonate;
 
trisodium 5-{4-chloro-6-
[2-(4,6-dichloro-5-
cyanopyrimidin-2-ylamino)-
propylamino]-
1,3,5-triazin-2-ylamino}-4-
hydroxy-3-(1-
sulfonatonaphthalen-2-ylazo)-
naphthalene-2,7-disulfonate;
 
trisodium 5-{4-chloro-6-
[2-(4,6-dichloro-5-
cyanopyrimidin-2-ylamino)-
1-methyl-ethy-
lamino]-1,3,5-triazin-2-
ylamino}-4-hydroxy-3-(1-
sulfonatonaphthalen-2-ylazo)-
naphthalene-2,7-disulfonate
414-620-8Eye Dam. 1
Skin Sens. 1
H318
H317
GHS05
GHS07
Dgr
H318
H317
   
611-117-00-71,3-bis{6-fluoro-4-[1,5-
disulfo-4-(3-amino-
carbonyl-1-ethyl-6-hydroxy-
4-methyl-pyrid-
2-on-5-ylazo)-phenyl-2-
ylamino]-1,3,5-triazin-2-
ylamino}propane lithium-, sodium salt
415-100-3149850-29-3Skin Sens. 1H317GHS07
Wng
H317   
611-118-00-2sodium 1,2-bis[4-[4-{4-
(4-sulfophenylazo)-
2-sulfophenylazo}-2-ureido-
phenyl-amino]-6-fluoro-1,3,5-
triazin-2-ylamino]-propane,
sodium salt
413-990-8 Skin Sens. 1H317GHS07
Wng
H317   
611-119-00-8tetrasodium 4-[4-chloro-6-(4-methyl-2-
sulfophenylamino)-1,3,5-
triazin-2-ylamino]-6-(4,5-
dimethyl-2-sulfophenylazo)-5-
hydroxynaphthalene-2,7-
disulfonate
415-400-4148878-22-2Eye Dam. 1
Skin Sens. 1
H318
H317
GHS05
GHS07
Dgr
H318
H317
   
611-120-00-35-{4-[5-amino-2-[4-(2-sulfoxyethylsulfonyl)
phenylazo]-4-sulfo-phenylamino]-6-chloro-
1,3,5-triazin-2-ylamino}-4-hydroxy-3-(1-
sulfo-naphthalen-2-ylazo)-naphthalene-2,7-
disulfonicacid sodium salt
418-340-7157707-94-3Eye Dam. 1
Aquatic Chronic 3
H318
H412
GHS05
Dgr
H318
H412
   
611-121-00-9main component 6 (isomer): asym. 1:2 Cr
(III)-complex of: A:
3-hydroxy-4-(2-hydroxy-
naphthalene-1-ylazo)naph-
thalene-1-sulfonic
acid, Na-salt and B:
1-[2-hydroxy-5-(4-methoxy-
phenylazo)phenylazo]naphtha-
lene-2-ol;
main component 8 (isomer): asym. 1:2 Cr-
complex of: A:
3-hydroxy-4-(2-hydroxy-
naphthalene-1-ylazo)-
naphthalene-1-sulfo-
nic acid, Na-salt and B:
1-[2-hydroxy-5-(4-
methoxy-phenylazo)-
phenylazo]-naphtha-
lene-2-ol
417-280-930785-74-1Eye Dam. 1
Aquatic Acute 1
Aquatic Chronic 1
H318
H400
H410
GHS05
GHS09
Dgr
H318
H410
   
611-122-00-4hexasodium
(di[N-(3-(4-[5-(5-amino-3-
methyl-1-phenylpyrazol-4-yl-
azo)-2,4-disulfo-anilino]-6-
chloro-1,3,5-triazin-2-yla-
mino)phenyl)-sulfamoyl](di-
sulfo)-phthalo-
cyaninato)nickel
417-250-5151436-99-6Eye Dam. 1
Skin Sens. 1
H318
H317
GHS05
GHS07
Dgr
H318
H317
   
611-123-00-X3-(2,4-bis(4-((5-(4,6-bis(2-
aminopropyla-mino)-1,3,5-
triazin-2-ylamino)-4-hydroxy-
2,7-disulfonaphthalen-3-
yl)azo)phenylamino)-1,3,5-
triazin-6-ylamino)propyldiethy-
lammonium lactate
424-310-4178452-66-9Eye Dam. 1H318GHS05
Dgr
H318   
611-124-00-5reaction mass of: pentasodium 5-amino-3-(5-{4-chloro-6-[4-(2-
sulfoxyethoxysulfo-
nato)phenylamino]-1,3,5-
triazin-2-ylamino}-2-sulfonato-
phenylazo)-6-[5-(2,3-
dibromopropionylamino)-2-
sulfonatophenylazo]-4-
hydroxynaphthalene-2,7-
disulfonate;
pentasodium 5-amino-6-[5-(2-
bromoacry-loylamino)-2-
sulfonatophenylazo]-3-(5-{4-
chloro-6-[4-(2-sulfoxyethoxy-
sulfonato)phenylamino]-1,3,5-
triazin-2-ylamino}-2-sulfo-
natophenylazo)-4-hydroxy-
naphthalene-2,7-disulfonate;
tetrasodium 5-amino-3-
[5-{4-chloro-6-[4-(vinyl-
sulfonyl)phenylamino]-1,3,5-
triazin-2-ylamino}-2-sulfona-
tophenylazo]-6-[5-(2,3-
dibromopropionylamino)-2-
sulfonatophe-
nylazo]-4-hydroxynaphthalene-
2,7-disulfonate
424-320-9 Eye Dam. 1
Aquatic Chronic 2
H318
H411
GHS05
GHS09
Dgr
H318
H411
   
611-125-00-0reaction mass of: Disodium 6-[3-carboxy-4,5-dihydro-5-
oxo-4-sulfonatophenyl)pyra-
zolin-4-yl-azo]-3-[2-oxido-4-
(ethensulfonyl)-5-methoxy-
phenylazo]-4-oxidonaphtha-
lene-2-sulfonate copper (II) complex;
Disodium 6-[3-carboxy-
4,5-dihydro-5-oxo-
4-sulfonatophenyl)pyrazolin-4-
yl-azo]-3-[2-oxido-4-(2-
hydroxyethylsulfonyl)-5-metho-
xyphenylazo]-4-oxidonaph-
thalene-2-sulfonate copper (II) complex
423-940-7Eye Dam. 1
Aquatic Chronic 2
H318
H411
GHS05
GHS09
Dgr
H318
H411
   
611-126-00-62,6-bis-(2-(4-(4-amino-
phenylamino)-phe-
nylazo)-1,3-dimethyl-3H-
imidazolium)-4-dimethylamino-
1,3,5-triazine, dichloride
424-120-1174514-06-8Eye Dam. 1
Aquatic Acute 1
Aquatic Chronic 1
H318
H400
H410
GHS05
GHS09
Dgr
H318
H410
   
611-127-00-1pentasodium 4-amino-6-(5-
(4-(2-ethyl-phenylamino)-6-
(2-sulfatoethanesulfonyl)-1,3,5-
triazin-2-ylamino)-2-sulfona-
tophenylazo)-5-hydroxy-3-(4-
(2-sulfatoethanesulfonyl)phe-
nylazo)naphthalene-2,7-
disulfonate
423-790-2Eye Dam. 1
Skin Sens. 1
Aquatic Chronic 3
H318
H317
H412
GHS05
GHS07
Dgr
H318
H317
H412
  G
611-128-00-7N,N'-bis{6-chloro-4-[6-(4-
vinylsulfonylphenylazo)-2,7-
disulfonicacid-5-hydroxynapht-
4-ylamino]-1,3,5-triazin-2-yl}-
N-(2-hydroxyethyl)ethane-1,2-
diamine, sodium salt
419-500-9171599-85-2Eye Dam. 1
Skin Sens. 1
H318
H317
GHS05
GHS07
Dgr
H318
H317
   
611-129-00-2reaction mass of:
5-[(4-[(7-amino-1-hyd-
roxy-3-sulfo-2-naphthyl)azo]-
2,5-diethoxyphenyl)azo]-2-
[(3-phosphonophenyl)azo]
benzoic acid;
5-[(4-[(7-amino-1-hydroxy-3-
sulfo-2-naphthyl)azo]-2,5-
diethoxyphenyl)azo]-3-[(3-
phosphonophenyl)azo]ben-
zoic acid
418-230-9163879-69-4Expl. 1.3
(*)(*)(*)(*)
Repr. 2
STOT RE 2 (*)
Skin Sens. 1
Aquatic Chronic 2
H203
H361f
(*)(*)(*)
H373 (*)(*)
H317
H411
GHS01
GHS08
GHS07
GHS09
Dgr
H203
H361f
(*)(*)(*)
H373 (*)(*)
H317
H411
   
611-130-00-8tetra-ammonium
2-[6-[7-(2-carboxylato-
phenylazo)-8-hydroxy-3,6-
disulfonato-1-
naphthylamino]-4-hydroxy-
1,3,5-triazin-2-ylamino]benzoate
N-methyl-N-2,4,6-tetra-
nitroaniline;
418-520-5183130-96-3Eye Irrit. 2
Aquatic Chronic 3
H319
H412
GHS07
Wng
H319
H412
   
611-131-00-32-[2-hydroxy-3-(2-
chlorophenyl)carbamoyl-
1-naphthylazo]-7-[2-hydroxy-
3-(3-methylphenyl)carbamoyl-
1-naphthylazo]fluoren-9-one
420-580-2151798-26-4Repr. 1B
Aquatic Chronic 4
H360D
(*)(*)(*)
H413
GHS08
Dgr
H360D
(*)(*)(*)
H413
   
611-132-00-9pentasodium
bis{7-[4-(1-butyl-5-cyano-1,2-
dihydro-2-hydroxy-4-methyl-
6-oxo-3-pyridylazo)phenyl-
sulfonylamino]-5'-nitro-3,3'-
disulfonatonaphthalene-2-
azobenzene-1,2'-
diolato} chromate (III)
419-210-2178452-71-6Eye Dam. 1
Aquatic Chronic 3
H318
H412
GHS05
Dgr
H318
H412
   
611-133-00-4Product by process iron complex of azo dyestuffs obtained by coupling a mixture of diazotized
2-amino-1-hydroxybenzene-4-
sulfanilide and 2-amino-1-
hydroxybenzene-4-sulfonamide with resorcin, the obtained mixture being subsequently submitted to a second coupling reaction with a mixture of diazotized
3-aminobenzene-1-sulfonic acid
(metanilic acid) and
4'-amino-4-nitro-1,1'-
diphenylamine-2-sulfonic acid and metallization with ferric chloride, sodium salt
419-260-5Eye Dam. 1
Aquatic Chronic 2
H318
H411
GHS05
GHS09
Dgr
H318
H411
   
611-134-00-Xtrisodium 2-{α[2-
hydroxy-3-[4-chloro-6-[4-
(2,3-dibromopropionylamino)-
2-sulfonatophenylamino]-
1,3,5-triazin-2-ylamino]-5-
sulfonatophenylazo]-
benzylidenehydra-
zino}-4-sulfonatobenzoate, copper complex
423-770-3Eye Dam. 1
Aquatic Chronic 2
H318
H411
GHS05
GHS09
Dgr
H318
H411
   
611-135-00-5reaction product of:
2-[[4-amino-2-ureido-
phenylazo]-5-[(2-(sulfo-
oxy)ethyl)sulfonyl]]
benzenesulfonic acid with 2,4,6-trifluoropyrimidine and partial hydrolysis to the corresponding vinylsulfonyl derivative, mixed potassium/sodium salt
424-250-9Eye Dam. 1
Aquatic Chronic 3
H318
H412
GHS05
Dgr
H318
H412
   
611-136-00-02-{4-(2-ammoniopropyl-
amino)-6-[4-hydroxy-3-(5-
methyl-2-methoxy-4-sulfamoyl-
phenylazo)-2-sulfonatonaphth-
7-ylamino]-1,3,5-triazin-2-
ylamino}-2-aminopropylformate
424-260-3Repr. 2
Eye Dam. 1
Aquatic Chronic 2
H361f
(*)(*)(*)
H318
H411
GHS05
GHS08
GHS09
Dgr
H361f
(*)(*)(*)
H318
H411
   
611-137-00-66-tert-butyl-7-chloro-3-tridecyl-
7,7a-dihydro-1H-pyrazolo[5,1-
c]-1,2,4-triazole
419-870-1159038-16-1Aquatic Chronic 4H413H413